| Deregulation of PRDM5 promotes cell proliferation by regulating JAK/STAT signaling pathway through SOCS1 in human lung adenocarcinoma. | Deregulation of PRDM5 promotes cell proliferation by regulating JAK/STAT signaling pathway through SOCS1 in human lung adenocarcinoma.
Ren Y, Wang Y, Fang L, Ma M, Ge L, Su C, Xin L, He J, Yang J, Liu X., Free PMC Article | 03/2/2023 |
| Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma. | Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.
Guo J, Yang Q, Wei S, Shao J, Zhao T, Guo L, Liu J, Chen J, Wang G., Free PMC Article | 07/16/2022 |
| PRDM5 suppresses oesophageal squamous carcinoma cells and modulates 14-3-3zeta/Akt signalling pathway. | PRDM5 suppresses oesophageal squamous carcinoma cells and modulates 14-3-3zeta/Akt signalling pathway.
Zhang C, Liu Z, Sheng Y, Wu B, Song Y, Ye G, Qi Y, Zhao S. | 03/26/2022 |
| More than meets the eye: Expanding and reviewing the clinical and mutational spectrum of brittle cornea syndrome. | More than meets the eye: Expanding and reviewing the clinical and mutational spectrum of brittle cornea syndrome.
Dhooge T, Van Damme T, Syx D, Mosquera LM, Nampoothiri S, Radhakrishnan A, Simsek-Kiper PO, Utine GE, Bonduelle M, Migeotte I, Essawi O, Ceylaner S, Al Kindy A, Tinkle B, Symoens S, Malfait F. | 01/29/2022 |
| Silencing of PRDM5 increases cell proliferation and inhibits cell apoptosis in glioma. | Silencing of PRDM5 increases cell proliferation and inhibits cell apoptosis in glioma.
Wang X, Chang H, Gao G, Su B, Deng Q, Zhou H, Wang Q, Lin Y, Ding Y. | 10/30/2021 |
| Truncations may be the primary mutation type in PITX2. Glaucoma onset may be earlier in patients with mutations in PITX2 than in those without mutations in PITX2 and FOXC1. A block of the anterior chamber angle by the end of the iris might represent the main factor influencing the development of glaucoma in ARS patients with an asymmetric aniridia phenotype. | Mutation Survey of Candidate Genes and Genotype-Phenotype Analysis in 20 Southeastern Chinese Patients with Axenfeld-Rieger Syndrome.
Wang X, Liu X, Huang L, Fang S, Jia X, Xiao X, Li S, Guo X. | 10/19/2019 |
| Inhibiting PRDM5 expression by siRNA attenuated the IFN-gamma-triggered accumulation of active caspase-3 and cleaved PARP in intestinal epithelial cells. Moreover, flow cytometry assay and CCK-8 analysis revealed that PRDM5 knockdown significantly alleviated the IFN-gamma-induced cellular apoptosis in HT29 cells. | PRDM5 promotes the apoptosis of epithelial cells induced by IFN-γ during Crohn's disease.
Wu H, Wang L, Zhang D, Qian J, Yan L, Tang Q, Ni R, Zou X. | 03/31/2018 |
| Both Prdm 4 and Prdm 5 are expressed in human corneal endothelium, primary hCECs and in HCECs-12 cells, characterised by expression of the Na(+)/K(+)-ATPase. | Identification of Prdm genes in human corneal endothelium.
Rolev K, O'Donovan DG, Georgiou C, Rajan MS, Chittka A., Free PMC Article | 08/12/2017 |
| The miR-182 promoter is rarely methylated in epithelial ovarian cancers (EOCs), and its methylation status is associated with lower miR-182 expression. Deletion of the PRDM5 locus may play a supportive role in miR-182 overexpression in EOC. miR-182 is an unfavorable prognostic factor in EOC. | Molecular bases of aberrant miR-182 expression in ovarian cancer.
Marzec-Kotarska B, Cybulski M, Kotarski JC, Ronowicz A, Tarkowski R, Polak G, Antosz H, Piotrowski A, Kotarski J. | 07/1/2017 |
| The current study revealed a novel mutation in the PRDM5 gene in a Brittle cornea syndrome (BCS) family and recurrent mutation in a sporadic BCS patient. | Identification of Mutations in the PRDM5 Gene in Brittle Cornea Syndrome.
Micheal S, Khan MI, Islam F, Akhtar F, Qamar R, Tassignon MJ, Loeys B, den Hollander AI. | 03/11/2017 |
| Genetic variants in PRDM5 can lead to various syndromic and nonsyndromic disorders affecting the anterior segment of the eye. | Whole exome sequencing identifies a heterozygous missense variant in the PRDM5 gene in a family with Axenfeld-Rieger syndrome.
Micheal S, Siddiqui SN, Zafar SN, Venselaar H, Qamar R, Khan MI, den Hollander AI., Free PMC Article | 10/22/2016 |
| Defective interaction of PRDM5 with repressive complexes, and dysregulation of H3K9me2, play a role in PRDM5-associated disease. | A role for repressive complexes and H3K9 di-methylation in PRDM5-associated brittle cornea syndrome.
Porter LF, Galli GG, Williamson S, Selley J, Knight D, Elcioglu N, Aydin A, Elcioglu M, Venselaar H, Lund AH, Bonshek R, Black GC, Manson FD., Free PMC Article | 08/27/2016 |
| Reduced expression of PRDM5 was observed in the cornea and retina of brittle cornea syndrome patients. | Bruch's membrane abnormalities in PRDM5-related brittle cornea syndrome.
Porter LF, Gallego-Pinazo R, Keeling CL, Kamieniorz M, Zoppi N, Colombi M, Giunta C, Bonshek R, Manson FD, Black GC., Free PMC Article | 07/16/2016 |
| These data suggest that PRDM5 is a relevant tumour suppressor gene that is frequently targeted in colorectal tumourigenesis. | Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.
Bond CE, Bettington ML, Pearson SA, McKeone DM, Leggett BA, Whitehall VL., Free PMC Article | 01/16/2016 |
| PRDM2, PRDM5, PRDM16 promoters are methylated and their expression is suppressed in lung cancer cells. | Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.
Tan SX, Hu RC, Liu JJ, Tan YL, Liu WE., Free PMC Article | 02/28/2015 |
| Data provide the first causal link between Prdm5 loss and intestinal carcinogenesis, and uncover an extensive and novel PRDM5 target repertoire likely facilitating the tumor-suppressive functions of PRDM5. | Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression.
Galli GG, Multhaupt HA, Carrara M, de Lichtenberg KH, Christensen IB, Linnemann D, Santoni-Rugiu E, Calogero RA, Lund AH. | 09/6/2014 |
| Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma. | Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma.
Tan SX, Hu RC, Tan YL, Liu JJ, Liu WE. | 06/28/2014 |
| Frequent epigenetic silencing of PRDM5 is involved in multiple tumorigeneses, which could serve as a tumor biomarker | The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors.
Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y, Poon FF, Wang X, Ying Y, Yeo W, Srivastava G, Tsao SW, Yu J, Sung JJ, Huang S, Chan AT, Tao Q., Free PMC Article | 05/19/2012 |
| ZNF469 and PRDM5, two genes that when mutated cause brittle cornea syndrome, participate in the same regulatory pathway. | Mutations in PRDM5 in brittle cornea syndrome identify a pathway regulating extracellular matrix development and maintenance.
Burkitt Wright EMM, Spencer HL, Daly SB, Manson FDC, Zeef LAH, Urquhart J, Zoppi N, Bonshek R, Tosounidis I, Mohan M, Madden C, Dodds A, Chandler KE, Banka S, Au L, Clayton-Smith J, Khan N, Biesecker LG, Wilson M, Rohrbach M, Colombi M, Giunta C, Black GCM., Free PMC Article | 08/20/2011 |
| Data show that reduced expression of PRDM5 may play an important role in the pathogenesis and/or development of cervical cancer, and is considered to be caused in part by aberrant DNA methylation. | DNA methylation and carcinogenesis of PRDM5 in cervical cancer.
Cheng HY, Chen XW, Cheng L, Liu YD, Lou G. | 11/27/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | A systematic gene-based screen of chr4q22-q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts.
Kalsi G, Kuo PH, Aliev F, Alexander J, McMichael O, Patterson DG, Walsh D, Zhao Z, Schuckit M, Nurnberger J Jr, Edenberg H, Kramer J, Hesselbrock V, Tischfield JA, Vladimirov V, Prescott CA, Dick DM, Kendler KS, Riley BP., Free PMC Article | 06/30/2010 |
| Results identify PRDM5, which acts as a sequence-specific, DNA binding transcription factor that targets hematopoiesis-associated protein-coding and microRNA genes, some of which are targets of Gfi1. | Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5.
Duan Z, Person RE, Lee HH, Huang S, Donadieu J, Badolato R, Grimes HL, Papayannopoulou T, Horwitz MS., Free PMC Article | 01/21/2010 |
| Data suggest that epigenetic alteration of PRDM5 (e.g., methylation of its 5'-CpG island or trimethylation of Lys(27) of histone H3) likely plays a key role in the progression of gastrointestinal cancers and may be a useful molecular marker. | PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer.
Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T. | 01/21/2010 |
| PRDM5 caused G2/M arrest and apoptosis upon infection of tumor cells. These results suggest that inactivation of PRDM5 may play a role in carcinogenesis. | PRDM5 is silenced in human cancers and has growth suppressive activities.
Deng Q, Huang S. | 01/21/2010 |